TRUSCARE MEDICAL CO., LTD.
China
Manufacturer/ Producer
TrusCare Medical Co., LTD., is an ISO13485 certified firm established in Nantong, Jiangsu, China. It is a high-tech leading enterprise engaging in manufacturing and distributing a wide range of medical equipment. Our company covers an area of 17000 square meters, and the registered capital is USD 3, 608, 000.00. Now we have built a Class 100, 000 Cleanroom with 2590 M2, a Sterilizing Workshop with 700 M2, a inspection Lab with 120 M2, a Storage with 1500 M2, and also matched office building, staff quarter, and mess hall. By complete sets of advanced equipments, we have the capacity of 30 millions of infusion sets per year, and have successfully marketed all our products to Asia, North America, Europe, Oceania, etc. Currently TrusCare mainly offer 4 series products including I.V. set series (Infusion set, Blood transfusion set, Extension Tub, Scalp vein set), Syringe, Sample Containers, Blood collection tube. If quantities are sufficient TrusCare can also offer OEM servise.
Website
Manufacturer/ Producer
#201-2, Building 1, Yongxinjiayuan
226005 Nantong - China
Company info
Key figures
-
- Company headcount
- 101 – 200
Organisation
-
- Year established
- 1994
-
- Main activity
- Manufacturer/ Producer
Activities of TRUSCARE MEDICAL CO., LTD.
- Medical and surgical instruments
- syringes for medical use
- infusion and transfusion sets
europages also recommends
A selection of companies related to the activity:
A selection of products that might interest you
MPS MICRO PRECISION SYSTEMS AG
Switzerland
Novostia, a Swiss startup founded in 2017, has entrusted MPS with the manufacture of its TRIFLO artificial valve, a revolutionary aortic prosthesis on several levels. Thanks to its aerodynamic design, the presence of three leaflets and the absence of physical pivot axes for the leaflets, the TRIFLO valve aims to satisfy the following three criteria: - A device lifespan at least equal to that of the patient, to avoid the need for a second surgical procedure. This means more than 30 million flap openings and closures per year, with no leaks, blockages, cracks, ruptures or flap escapes. - The artificial valve must not lead to thrombosis, so that patients do not need to take anticoagulants. - Operation (flap opening and closing, blood flow through the valve) must be as silent as possible, so as not to disturb the patient or those around him, day or night. The TRIFLO device is in clinical trial and is not approved for sale.
Request for quotes
Create one request and get multiple quotes form verified suppliers.
- Only relevant suppliers
- Data privacy compliant
- 100% free